Beryl Drugs Past Earnings Performance
Past criteria checks 5/6
Beryl Drugs has been growing earnings at an average annual rate of 4.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 20.7% per year. Beryl Drugs's return on equity is 13.1%, and it has net margins of 3.9%.
Key information
4.5%
Earnings growth rate
4.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 20.7% |
Return on equity | 13.1% |
Net Margin | 3.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Beryl Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 299 | 12 | 19 | 0 |
30 Sep 23 | 304 | 10 | 19 | 0 |
30 Jun 23 | 301 | 11 | 18 | 0 |
31 Mar 23 | 269 | 8 | 17 | 0 |
31 Dec 22 | 242 | 2 | 15 | 0 |
30 Sep 22 | 193 | 0 | 15 | 0 |
30 Jun 22 | 149 | -8 | 13 | 0 |
31 Mar 22 | 146 | -7 | 13 | 0 |
31 Dec 21 | 172 | -1 | 14 | 0 |
30 Sep 21 | 161 | -1 | 13 | 0 |
30 Jun 21 | 160 | 8 | 12 | 0 |
31 Mar 21 | 141 | 2 | 12 | 0 |
31 Dec 20 | 111 | -4 | 11 | 0 |
30 Sep 20 | 113 | -2 | 11 | 0 |
30 Jun 20 | 113 | -5 | 10 | 0 |
31 Mar 20 | 128 | 0 | 10 | 0 |
31 Dec 19 | 120 | 7 | 9 | 0 |
30 Sep 19 | 128 | 8 | 9 | 0 |
30 Jun 19 | 130 | 7 | 9 | 0 |
31 Mar 19 | 130 | 6 | 9 | 0 |
31 Dec 18 | 143 | 8 | 9 | 0 |
30 Sep 18 | 148 | 7 | 9 | 0 |
30 Jun 18 | 145 | 11 | 8 | 0 |
31 Mar 18 | 152 | 10 | 8 | 0 |
31 Dec 17 | 141 | 7 | 7 | 0 |
30 Sep 17 | 130 | 5 | 8 | 0 |
30 Jun 17 | 128 | 1 | 9 | 0 |
31 Mar 17 | 113 | -4 | 10 | 0 |
31 Dec 16 | 102 | 0 | 11 | 0 |
30 Sep 16 | 105 | 1 | 12 | 0 |
30 Jun 16 | 115 | 2 | 13 | 0 |
31 Mar 16 | 131 | 2 | 12 | 0 |
31 Dec 15 | 150 | 1 | 14 | 0 |
30 Sep 15 | 150 | 1 | 22 | 0 |
30 Jun 15 | 146 | 3 | 40 | 0 |
31 Mar 15 | 133 | 1 | 12 | 0 |
31 Dec 14 | 121 | 1 | 24 | 0 |
30 Sep 14 | 130 | 2 | 22 | 0 |
30 Jun 14 | 137 | 2 | 22 | 0 |
31 Mar 14 | 146 | 3 | 21 | 0 |
31 Dec 13 | 135 | 2 | 17 | 0 |
30 Sep 13 | 143 | 2 | 22 | 0 |
30 Jun 13 | 168 | 4 | 38 | 0 |
Quality Earnings: 524606 has high quality earnings.
Growing Profit Margin: 524606's current net profit margins (3.9%) are higher than last year (0.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524606's earnings have grown by 4.5% per year over the past 5 years.
Accelerating Growth: 524606's earnings growth over the past year (415.9%) exceeds its 5-year average (4.5% per year).
Earnings vs Industry: 524606 earnings growth over the past year (415.9%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 524606's Return on Equity (13.1%) is considered low.